Savara Presents New Data From Phase 3 IMPALA-2 Showing Molgramostim Beneficial In aPAP Patients Regardless Of Disease Severity
Benzinga Newsdesk 1 year ago
News
– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% –– Changes in DLco%, the Primary Endpoint in IMPALA-2, Were Significantly Correlated
– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% –
– Changes in DLco%, the Primary Endpoint in IMPALA-2, Were Significantly Correlated with Changes in Measures of Quality of Life, Patient Functionality, and Surfactant Burden in Patients with aPAP –
– Savara's Partner, TrilliumBiO, Presented Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPAP –